Investor Relations


Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Events & Presentations


October 30, 2018 8:00 AM EDT
Q3 2018 Incyte Corporation Earnings Conference Call


September 13, 2018 10:00 AM EDT
Morgan Stanley 16th Annual Global Healthcare Conference

July 31, 2018 8:00 AM EDT
Q2 2018 Incyte Corporation Earnings Conference Call

June 21, 2018 1:00 PM EDT
2018 Investor & Analyst Event

SEC Filings

Filing date Description Filing Group View

A statement of beneficial ownership of common stock by certain persons


An amendment to the SC 13G filing


An amendment to the SC 13G filing


Investor Contacts

Michael Booth D.Phil
Vice President, Investor Relations
Phone: 302.498.5914

Lauren Kwiecinski
Senior Director, Investor Relations
Phone: 302.498.6141

P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536